IP Library Granted Patent US 9,272,017
Granted Patent B2
US 9,272,017 · App. 13/763,301 · Granted Mar 1, 2016

Pharmaceutical compositions including a portion of the C-terminus of FGF23

Inventors: Moosa Mohammadi (Scarsdale, NY); Regina Goetz (New York, NY)
Assignee: New York University
A61K38/1825A61K31/59A61K38/17A61K38/1709A61K45/06G01N21/84G01N30/00G01N33/573G01N33/68
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,272,017
App. No.
13/763,301
Granted
Mar 1, 2016
Kind
B2
Abstract

The present invention is directed to a pharmaceuticalm composition comprising a peptide comprising at least a portion corresponding to the C-terminus of FGF23 and an additive selected from the group consisting of vitamin D and a vitamin D receptor agonist.

Claims (8)

1. A pharmaceutical composition comprising:

a peptide comprising at least a portion corresponding to the C-terminus of FGF23, wherein the portion corresponding to the C-terminus of FGF23 consists of the amino acid sequence of SEQ ID NO:12 and

an additive, wherein the additive is a vitamin D receptor agonist and is formulated in combination with said peptide for simultaneous administration.

2. The pharmaceutical composition according to claim 1 , wherein the peptide consists of SEQ ID NO:12.

3. The pharmaceutical composition according to claim 1 further comprising a pharmaceutically acceptable carrier.

4. The pharmaceutical composition according to claim 1 , wherein the composition is in the form of a tablet, capsule, powder, solution, suspension, or emulsion.

5. The pharmaceutical composition according to claim 1 , wherein the composition is formulated for administration to a subject orally, parenterally, subcutaneously, intravenously, intramuscularly, intraperitoneally, by intranasal instillation, by implantation, by intracavitary or intravesical instillation, intraocularly, intraarterially, intralesionally, transdermally, or by application to mucous membranes.

6. The pharmaceutical composition according to claim 1 , wherein the additive is vitamin D.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 20, 2016
From: MOHAMMADI, MOOSA; GOETZ, REGINA; ELISEENKOVA, ANNA V.
To: NEW YORK UNIVERSITY
Reel/Frame 039196/0509 →
Continuity (3)
Continuation 12915801 · Oct 29, 2010
Provisional Application 61256361 · Oct 30, 2009
Related Publication 20130172275A1 · Jul 4, 2013